Aura Biosciences, Inc. (AURA)
NASDAQ: AURA · Real-Time Price · USD
8.75
-0.17 (-1.91%)
Nov 20, 2024, 4:00 PM EST - Market closed
Aura Biosciences Employees
As of December 31, 2023, Aura Biosciences had 89 total employees, including 88 full-time and 1 part-time employees. The number of employees increased by 17 or 23.61% compared to the previous year.
Employees
89
Change (1Y)
17
Growth (1Y)
23.61%
Revenue / Employee
n/a
Profits / Employee
-$935,011
Market Cap
437.08M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89 | 17 | 23.61% |
Dec 31, 2022 | 72 | 20 | 38.46% |
Dec 31, 2021 | 52 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Emergent BioSolutions | 1,600 |
Health Catalyst | 1,300 |
Pacific Biosciences of California | 796 |
National Research | 435 |
Xeris Biopharma Holdings | 377 |
REGENXBIO | 344 |
Allogene Therapeutics | 233 |
Perspective Therapeutics | 119 |
AURA News
- 4 weeks ago - Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value - Seeking Alpha
- 4 weeks ago - Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease - Benzinga
- 4 weeks ago - Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial - GlobeNewsWire
- 5 weeks ago - 3 Small-Cap Stocks Ready to Deliver Significant Growth - Benzinga
- 2 months ago - Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + - Seeking Alpha
- 2 months ago - Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company - Seeking Alpha
- 2 months ago - Aura Biosciences Touts Promising Data From Eye Cancer Candidate - Benzinga
- 2 months ago - Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma - GlobeNewsWire